PRKCSH

Across TCGA pan-cancer cohorts, PRKCSH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRKCSH data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRKCSH mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRKCSH expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where PRKCSH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.620	0.894	.003	44	view →
LUAD	DFS	Tertile	III,IV	0.908	0.321	.007	17	view →
HNSC	OS	Median	II,III,IV	0.615	0.834	.004	9	view →
LSCC	OS	Tertile	All	0.678	0.893	.029	5	view →
GBM	DFS	Median	All	0.793	0.596	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRKCSH–CCRCC (DFS)

Open the CCRCC breakdown →